HC Wainwright Predicts Reduced Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2024 EPS estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $3.64 per share for the year, down from their prior estimate of $4.01. HC Wainwright has a "Buy" rating and a $221.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $2.88 per share. HC Wainwright also issued estimates for Krystal Biotech's Q4 2024 earnings at $1.81 EPS, FY2025 earnings at $5.57 EPS, FY2027 earnings at $9.34 EPS and FY2028 earnings at $9.76 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same period in the previous year, the business earned ($0.67) EPS. Krystal Biotech's revenue was up 879.9% compared to the same quarter last year.

Other research analysts have also recently issued research reports about the company. Chardan Capital increased their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a research note on Monday, August 5th. Evercore ISI increased their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research note on Monday, August 12th. Stifel Nicolaus increased their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, William Blair raised Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $197.00.

Krystal Biotech Trading Up 1.3 %

Shares of KRYS traded up $2.36 during mid-day trading on Thursday, reaching $185.45. 202,507 shares of the stock traded hands, compared to its average volume of 329,947. The firm has a fifty day moving average price of $181.20 and a 200 day moving average price of $180.29. The company has a market cap of $5.33 billion, a price-to-earnings ratio of 104.77 and a beta of 0.82. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently modified their holdings of KRYS. Jamison Private Wealth Management Inc. purchased a new stake in shares of Krystal Biotech during the second quarter worth about $28,000. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company's stock worth $28,000 after buying an additional 93 shares during the period. Key Financial Inc purchased a new stake in Krystal Biotech in the second quarter worth about $28,000. Blue Trust Inc. lifted its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock worth $30,000 after buying an additional 163 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in Krystal Biotech in the third quarter worth about $53,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).